- Home
- NMT vs STRO Comparison
NMT vs STRO Comparison
Compare NMT & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- STRO
- Stock Information
- Founded
- NMT 1993
- STRO 2003
- Country
- NMT United States
- STRO United States
- Employees
- NMT N/A
- STRO N/A
- Industry
- NMT Finance/Investors Services
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMT Finance
- STRO Health Care
- Exchange
- NMT Nasdaq
- STRO Nasdaq
- Market Cap
- NMT 107.8M
- STRO 94.9M
- IPO Year
- NMT N/A
- STRO 2018
- Fundamental
- Price
- NMT $11.47
- STRO $0.95
- Analyst Decision
- NMT
- STRO Hold
- Analyst Count
- NMT 0
- STRO 7
- Target Price
- NMT N/A
- STRO $1.97
- AVG Volume (30 Days)
- NMT 19.1K
- STRO 1.6M
- Earning Date
- NMT 01-01-0001
- STRO 11-10-2025
- Dividend Yield
- NMT 3.21%
- STRO N/A
- EPS Growth
- NMT N/A
- STRO N/A
- EPS
- NMT N/A
- STRO N/A
- Revenue
- NMT N/A
- STRO $104,473,000.00
- Revenue This Year
- NMT N/A
- STRO $65.48
- Revenue Next Year
- NMT N/A
- STRO N/A
- P/E Ratio
- NMT N/A
- STRO N/A
- Revenue Growth
- NMT N/A
- STRO N/A
- 52 Week Low
- NMT $9.05
- STRO $0.52
- 52 Week High
- NMT $10.93
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- NMT 42.08
- STRO 45.59
- Support Level
- NMT $11.42
- STRO $1.01
- Resistance Level
- NMT $11.60
- STRO $1.20
- Average True Range (ATR)
- NMT 0.09
- STRO 0.12
- MACD
- NMT -0.01
- STRO -0.02
- Stochastic Oscillator
- NMT 23.68
- STRO 8.09
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.